Abstract
The clinical practice has requiredthat novel typesof basal insulin analogues be developed. They are characterised bya lower intraindividual variabilityof the effect, which meansbetter predictability of the effect and reduction in the riskof nocturnal hypoglycaemia, in particular.
This group includes insulin degludec, insulin glarginein aconcentrationof 300 IU, and pegylated insulin lispro, which exhibitshigher affinityto the effect directly in the hepatic cell. The three novel typesof basal analogueswill all improve the safetyof treatmentin both type 1 and type 2 diabetes.
Premixed analogues have also retained their place in the treatment, with their advantage beingconcurrentfasting as well as postprandial glycaemia intervention. They are particularly intendedfor patients witha stableeverydaylife.